LAVA Therapeutics(LVTX) - 2024 Q4 - Annual Results

Exhibit 99.1 LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update Utrecht, The Netherlands, and Philadelphia, PA, US – March 28, 2025 – LAVA Therapeutics N.V. (NASDAQ: LVTX, "LAVA," "the Company"), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced recent corporate highlights and financial results for the fourth quarter and year ended December 31, 2024. "LAVA' ...